JP2010100781A - Polymer, transepithelial absorption accelerator, and formulation for medicine - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a polymer with which absorption of a drug is improved and a stimulus imparted to a living body in drug administration is reduced, and to provide a transepithelial absorption accelerator, and formulation for medicine. <P>SOLUTION: The polymer has a membrane permeable peptide in the side chain. At least one amino acid constituting the membrane permeable peptide is preferably a basic amino acid, Furthermore, the polymer may exist singly by itself, or may have a crosslinked structure via covalent bonding or via non-covalent bonding type interaction. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to a polymer, a transepithelial absorption promoter, and a pharmaceutical preparation, and particularly relates to a technique for promoting transepithelial absorption of a substance.

  It has been reported that when a drug is administered via a site such as the small intestine, large intestine, rectum, nasal cavity, oral cavity, vagina, and skin, the drug is absorbed through a simple diffusion or transport system such as a transporter. Not all drugs are easily absorbed. Rather, absorption through these sites is easily affected by properties such as the drug's own solubility, molecular weight, melting point, hydrophilic and hydrophobic balance, etc., and the necessary and sufficient amount of drug is absorbed into the body. Is less.

  One of the causes is a barrier of drug absorption by epithelial cells in the mucous membrane such as the digestive tract and nasal cavity and keratinocytes in the skin. In fact, due to this barrier, there is a report that drugs absorbed from the skin are limited to those having a molecular weight of 500 or less and a melting point of 200 ° C. or less (Non-Patent Document 1). In addition, many drugs that are easily absorbed orally have a molecular weight of 500 or less and an oil / water partition coefficient of −0.4 to 5.6, as described in “Lipinski's Rule of 5.” There is a report (Non-Patent Document 2).

However, due to recent developments in protein engineering and genetic engineering, many usefulnesses of not only low molecular weight drugs but also high molecular weight drugs have been found. In addition, even for low molecular weight drugs, there is a demand for the development of drug delivery technology that increases the effect and reduces side effects by delivering the required amount of drug to the required site for the required time (non-) Patent Document 3).
T. T. K. Gosh et al., Transdermal and Topical Drug Delivery Systems, Interph Press, Inc. Illinois, USA, 1997 C. A. Lipinski et al., Advanced Drug Delivery Reviews, 23, 3-25, 1997 Hashida Mitsuru, Drug Delivery System, Chemical Doujin, 1995

  Under such circumstances, in order to deliver a necessary amount of the drug to the target site, it is necessary to overcome the absorption barrier of the drug, and absorption accelerators are attracting attention as a means for that purpose. Conventionally, surfactants, fatty acids, alcohols, and the like have been disclosed as absorption enhancers. However, even if these absorption enhancers are used, the necessary and sufficient amount of drug absorption cannot be obtained or the drug is absorbed. There is a problem that a stimulus appears at the absorption site. In the latter case, if the absorption enhancer is absorbed by the transepithelium, side effects may occur due to stimulation of the absorption enhancer itself.

  In order to solve these problems, the present inventors have intensively studied a novel absorption promoter, and as a result, have focused on a membrane-permeable peptide composed of amino acids derived from biological components. Futaki has focused on the basic peptide derived from the human immunodeficiency virus type 1 Tat protein as a membrane-penetrating peptide. As a result, the oligoarginine peptide is a proteoglycan that is a complex protein with sulfated polysaccharide on the cell surface. It has been found that it is concentrated on the cell surface by interacting with the enzyme and actively taken into the cell through a special endocytosis called macropinocytosis (S. Futaki, et.al., Current Protein and Peptide). Science, Vol. 4, pp. 87-96, 2003, S. Futaki, Advanced Drug Delivery Reviews, 57, 547-558, 2005, Shiro Futaki, Pharmacia, Vol. 44, No. 4, 321-325, 2008 . Rothbard et al. Reported that the synthesis of a conjugate of an arginine peptide and an immunosuppressive agent, cyclosporine, attempted to improve the transdermal absorbability of cyclosporine, and that the inflammatory reaction of the skin was suppressed ( JB Rothbard, et.al., Nat. Med., 6, 1253-1257, 2000). Furthermore, Kitaura et al. Reported that transepithelial absorption was improved by directly binding a peptide having one or more guanidinium groups to a peptide having incretin hormone activity (GLP-1, exendin, etc.). No.-517055).

  However, in these techniques, the membrane permeable peptide and the drug are chemically and / or physicochemically combined. For this reason, as a result of absorption of not only the drug but also the membrane-permeable peptide, there are concerns about side effects such as the aforementioned stimulation.

  The present invention has been made in view of the above circumstances, and provides a polymer, a transepithelial absorption promoter, and a pharmaceutical preparation that can improve drug absorption and can reduce irritation to a living body during drug administration. For the purpose.

  The present inventors, when a mixture of a target drug and a polymer in which a membrane-penetrating peptide is chemically bonded to a side chain is administered transepithelially, although the membrane-penetrating peptide interacts with proteoglycans of epithelial cells, The polymer itself is difficult to absorb because of its high molecular weight, and it is intended that only the absorption of the target drug is promoted. Specifically, the present invention provides the following.

  (1) A polymer having a membrane-penetrating peptide in the side chain.

  (2) The polymer according to (1), wherein at least one of the amino acids constituting the membrane-penetrating peptide is a basic amino acid.

  (3) The polymer according to (1) or (2), which has a crosslinked structure by covalent bond or a crosslinked structure by non-covalent interaction.

  (4) A transepithelial absorption promoter comprising the polymer according to any one of (1) to (3).

  (5) A pharmaceutical preparation comprising the transepithelial absorption promoter according to (4) and a drug.

  According to the present invention, by using a polymer having a membrane-penetrating peptide in the side chain, it is possible to simultaneously achieve improvement of transepithelial drug absorption and reduction of stimulation given to a living body.

  Hereinafter, although an example of an embodiment of the present invention is explained, the present invention is not limited to the following embodiment.

<Polymer>
The polymer according to the present invention has a so-called graft structure having a membrane-permeable peptide in the side chain of the trunk polymer. Such a polymer is less irritating when administered to skin, intranasal mucosa, etc., and can improve the absorption efficiency of the coexisting drug.

  The mechanism for promoting absorption of a drug by a transmembrane peptide varies depending on the type of transmembrane peptide used, but generally, the transmembrane peptide induces macropinocytosis of the cell and is taken into the cell, It is presumed that the membrane permeation of the drug is promoted. Therefore, conventionally, studies have been made to improve the membrane permeability of drugs by binding membrane-permeable peptides to drugs via covalent bonds or non-covalent interactions. However, in this method, not only the drug but also the membrane-permeable peptide is taken into the cell, and therefore there is a concern about irritation to the living body by the membrane-permeable peptide.

  In the present invention, it is possible to selectively improve the absorption of the coexisting drug by binding the membrane-penetrating peptide to the trunk polymer as a base. That is, macropinocytosis is induced by the membrane-penetrating peptide bound to the trunk polymer. At this time, the cells try to take in the polymer to which the membrane-permeable peptide is bound, but it is difficult to take in the macromolecule. This uptake inhibition becomes stronger by cross-linking the polymer by covalent bond or non-covalent interaction, and further improvement in safety can be expected.

  On the other hand, cells fail to take up macromolecules, but accidentally take in coexisting drugs into the cells. In addition, as long as there is a polymer with a membrane-penetrating peptide attached, the cell will repeatedly try to take up the macromolecule by macropinocytosis, so the absorbability of the accidentally incorporated drug is dramatically improved. . In a UFO catcher (registered trademark; one type of crane game), this theory is easy to understand, assuming that the stuffed animal to be picked up is fixed to the bottom of the device with a transparent string. In other words, it is impossible to lift the stuffed animal because it is fixed with a string, but in the process, it is possible to remove a bag that exists near the stuffed animal, which is not intended by the player. Moreover, since the player does not notice the fact that the stuffed animal is fixed with a transparent string, the player tries to take the stuffed animal over and over again. As a result, the number of traps that are accidentally acquired continues to increase selectively. In this example, sputum corresponds to a drug, but it suffices for the drug to be present in the vicinity of the polymer to which the membrane-penetrating peptide is bound, and the presence of some interaction between them is a sufficient condition, but the necessary condition is not. Note that the mechanisms described in this specification are all speculations and do not limit the present invention.

[Side chain (membrane-penetrating peptide)]
As used herein, the term “membrane-penetrating peptide” means that when administered to epithelial cells or animal cells in the state of coexisting with a desired drug, the permeability of the drug is improved as compared to the administration of the drug alone (for example, the permeation rate of Refers to any peptide that can be increased). Accordingly, the membrane-penetrating peptide may be appropriately selected depending on the type of drug that should promote absorption.

  Preferable specific examples of the membrane-penetrating peptide include a arginine oligomer in which 7 to 12 arginines are peptide-bonded, a basic peptide such as a peptide having an amino acid sequence of GRKKRRRRRPPQ (commonly called Tat), a peptide having an amino acid sequence of RQKIKIWFQNRRMKWKK (commonly called an antenna) And an amphiphilic basic peptide such as pedia) and a hydrophobic basic peptide such as a peptide having an amino acid sequence of GWTLNSAGYLLGKINLKALAALAKIL (commonly referred to as transportan).

  The membrane-penetrating peptide is composed of a plurality of amino acids. In order to improve the absorbability of the drug from the epithelium such as the intranasal mucosa, at least one of the amino acids is preferably a basic amino acid. . The basic amino acid may be either L-form or D-form, and may be appropriately selected according to the drug to be used.

  The basic amino acid is preferably arginine, ornithine, lysine, hydroxylysine or histidine, and is preferably selected from the group consisting of these. In order to improve the absorbability of the drug from the epithelium such as the intranasal mucosa, at least one of the basic amino acids is preferably a guanidino group-containing amino acid, and more preferably arginine. Arginine may be either L-form or D-form, and may be appropriately selected according to the drug to be used. The membrane-penetrating peptide may have other amino acids such as acidic amino acids and amphoteric amino acids in addition to basic amino acids.

  The ratio (molar ratio) of basic amino acids in all amino acids constituting the membrane-penetrating peptide is not particularly limited, but is preferably 50% or more, more preferably 75% or more, and most preferably 100%. Thereby, since the degree of promotion of the drug absorption efficiency per membrane-permeable peptide increases, a reduction in the required amount of the membrane-permeable peptide when synthesizing the polymer can be expected, and the synthesis cost can be reduced.

  The number of amino acids constituting the membrane-penetrating peptide is not particularly limited, but the number of amino acids is preferably 2 or more, more preferably 4 or more, in that the drug absorption efficiency can be sufficiently improved. .

  The above membrane-penetrating peptides may be isolated from natural materials or synthesized artificially. The specific procedure of preparation may follow a conventional method.

[Stem polymer]
The polymer backbone polymer according to the present invention is not particularly limited, but is preferably a hydrophilic polymer because of its excellent affinity with skin and mucous membranes. Here, the hydrophilic polymer means a water-soluble polymer or a polymer that swells in water. The water-soluble polymer as used herein refers to a polymer that, when added to water at a saturation concentration or lower under normal pressure, dissolves the total amount added to give a uniform solution. The time and temperature required for dissolving the polymer are not particularly limited.

  Examples of hydrophilic polymers include pectin, guar gum, agarose, mannan, glucomannan, polydextrose, alginic acid, lignin, chitin, chitosan, carrageenan, pectin, quince seed (malmello), xanthan gum, pullulan, cellulose, hemicellulose, methylcellulose. , Ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, starch, carboxyl starch, cationic starch, polysaccharides of dextrin or modified polysaccharides; water-soluble proteins such as albumin, casein, gelatin; polyacrylic acid and its esters Amides, polymethacrylic acid and esters thereof, amides, polyvinylamine and amides thereof (poly N-vinylacetamide, etc.) Polyvinylpyrrolidone, vinyl hydrophilic polymer such as polyvinyl alcohol; water-soluble polyurethane, and the like. The vinyl hydrophilic polymer may be a homopolymer composed of one type of monomer unit or a copolymer composed of two or more types of monomer units. The copolymer may be any type of random, block and graft.

  Among them, vinyl-based hydrophilic polymers composed of one or more monomer units selected from the group consisting of acrylic acid, N-vinylacetamide, vinylpyrrolidone, vinyl alcohol, or derivatives thereof have been widely used for external preparations and the like. In view of excellent safety.

  The trunk polymer preferably includes a monomer unit having a carboxyl group. As the monomer unit having a carboxyl group, in the case of polysaccharides or modified polysaccharides, for example, arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose and the like are carboxymethyl. In the case of a water-soluble protein, for example, glutamic acid, aspartic acid, etc .; in the case of a vinyl-based hydrophilic polymer, acrylic acid, methacrylic acid, crotonic acid, (anhydrous) maleic acid, itaconic acid , P-carboxylstyrene and the like. Of these, acrylic acid is preferred because of its good reactivity with the amino group of the membrane-penetrating peptide.

  When the molar ratio of the monomer unit having a carboxyl group in the trunk polymer is excessive, it is difficult to react with the amino group of the membrane-penetrating peptide. The ratio of the monomer unit having a carboxyl group to the total monomer unit of the trunk polymer is preferably 0.001 to 0.7 because the drug absorption promoting effect tends to be insufficient due to insufficient, and 0 More preferably, it is 0.01 to 0.6, and most preferably 0.01 to 0.5.

  By reacting the carboxyl group of the trunk polymer with the amino group of the membrane-penetrating peptide, the membrane-penetrating peptide can be most easily introduced through the amide bond as the side chain of the trunk polymer. However, the method for immobilizing the membrane-permeable peptide is not limited to this method, and the membrane-permeable peptide can be immobilized using a generally known chemical reaction.

  When the weight average molecular weight of the trunk polymer is large, the polymer itself is difficult to permeate the epithelium and can be expected to improve safety. Therefore, it is preferably 500 or more, and the number of repeating monomers is preferably 10 or more.

  In addition, in this invention, a weight average molecular weight means the weight average molecular weight of a polyethylene glycol (PEG) or a polyethylene oxide (PEO) conversion, or a pullulan when a GPC analysis is performed using an aqueous solvent.

[Production method]
The polymer of the present invention may be obtained by polymerizing a membrane-permeable peptide to a polymer constituting the trunk polymer according to a conventional method. The leaving group to be used and the specific synthesis procedure may be appropriately selected according to the polymer to be used and the membrane-permeable peptide.

<Transepithelial absorption promoter>
It has been confirmed that the transepithelial absorption enhancer comprising the above polymer has little irritation when administered to the epithelium such as intranasal mucosa and can improve the absorption efficiency of the coexisting drug. If a hydrophilic vinyl polymer is employed as the polymer backbone polymer, the polymer is excellent in versatility because it is hydrophilic and can be suitably used in a hydrous system. Therefore, it may be applied to the nasal cavity in various dosage forms containing a drug, for example, liquid or gel. As used herein, “epithelium” refers to the outer layer of cells that covers all of the freely open surface of the body, and includes skin and mucous membranes. The mucosa refers to nasal mucosa, oral mucosa, vaginal mucosa, rectal mucosa, ocular mucosa and the like, and also includes gastrointestinal mucosa such as stomach and intestine.

(Crosslinking)
In the present invention, the above polymer may be used alone or may have a crosslinked structure by a covalent bond or non-covalent interaction. Since the crosslinked body has a molecular weight larger than that of the above polymer, it is much less likely to penetrate the epithelium, and the safety can be greatly improved.

  Crosslinking methods include covalent or non-covalent interactions. As a covalent bond, a method of chemically bonding ethylenediamine to a carboxyl group in a polymer is common, but is not limited to this, and all methods used for crosslinking of a polymer are applicable. . In addition, the polymer can be crosslinked using a divalent or higher-valent metal or non-metal atom (for example, selected from the group consisting of aluminum, silicon, cadmium, boron, titanium, zinc, magnesium, and tin). In addition, electrostatic interactions other than crosslinking using metal ions, hydrogen bonds, hydrophobic bonds, π-stacking interactions, interactions by van der Waals attractive forces, and the like can be used as non-covalent interactions. Any one of the above covalent bonds or non-covalent interactions may be used, or a plurality thereof may be combined.

<Pharmaceutical preparation>
The pharmaceutical preparation of the present invention contains the transepithelial absorption promoter and a drug.

[Drug]
The pharmaceutical preparation of the present invention has an excellent transepithelial absorption promoting action of a drug. Therefore, the drug contained in the pharmaceutical preparation of the present invention may be either a systemic drug or a topical drug, and is not particularly limited. The drug can be arbitrarily selected according to the therapeutic purpose, and can be used alone or in combination of two or more.

  Examples of the drug used in the present invention include peptide and protein pharmaceuticals such as insulin and insulin secretagogues (for example, exendin-4, GLP-1), steroid hormones, nonsteroidal analgesic anti-inflammatory agents, mental Stabilizer, antihypertensive, ischemic heart disease, antihistamine, antiasthma, antiparkinson, cerebral circulation remedy, antiemetic, antidepressant, antiarrhythmic, anticoagulant, antigout, Antifungal, Antidementia, Sjogren's Syndrome, Narcotic Analgesic, Beta Blocker, β1 Agonist, β2 Agonist, Parasympathomimetic, Antitumor Agent, Diuretic, Antithrombotic, Histamine H1 Receptor Antagonists, histamine H2 receptor antagonists, antiallergic agents, smoking cessation aids, vitamins. The present invention relates to the promotion of transepithelial absorption of drugs. For example, those excellent in absorbability from the digestive tract may be outside the scope of application of the present invention.

  The specific compounding amount of the drug may be appropriately set according to the therapeutic purpose and dosage form.

(Optional component)
In addition to the drug and the transepithelial absorption promoter, arbitrary components can be appropriately blended within a range not impairing the effects of the present invention. Examples of such optional components include crosslinking agents, drug solubilizers, emulsifiers, humectants, cooling agents, inorganic powders, antioxidants, preservatives, dyes, pH adjusters, and crosslinking control agents.

<Example 1>
[Synthesis of polymers]
The outline of the synthesis procedure of the polymer according to an example of the present invention is as shown in the following reaction formula. A detailed procedure will be described below.

(Protonation)
10 g of “adHERO GE167” (manufactured by Showa Denko KK) which is a N vinylacetamide-sodium acrylate copolymer is dissolved in 1 L of ion-exchanged water, and an ion-exchange resin “Amberlyst 15DRY” (manufactured by Organo) is added to the solution 10 g was added and stirred. After stirring for 2 hours, the ion exchange resin was filtered off, and the filtrate was lyophilized to obtain 8.6 g of protonated N vinylacetamide-acrylic acid copolymer (GE167-H). As a result of neutralization titration of GE167-H according to a conventional method, it was confirmed that a: b = 93: 7 in the above reaction formula.

(Introduction of leaving group)
1.0 g of GE167-H was dissolved in 33 mL of N ′, N ′ dimethylformamide (DMF), and another 0.983 g of dicyclohexylcarbodiimide (DCC) was added. This solution was stirred for 10 minutes under ice cooling, and 0.548 g of succinic anhydride was added. Stirring was continued at 60 ° C. for 19 hours to carry out the reaction. After the reaction, 33 mL of ethanol was added, followed by reprecipitation in 1 L of acetonitrile, followed by drying under reduced pressure to obtain 0.740 g of GE167-OSu converted to succinimide ester.

(Introduction of transmembrane peptide)
36 mg of GE167-OSu was dissolved in 1.15 mL of DMF. To this, 350 μL of a DMF solution (1 mg / 10 μL) of octa D arginine (NH ₂ -rrrrrrrr, Hayashi Kasei Co., Ltd.) was mixed and shaken at 40 ° C. for 24 hours to carry out a reaction. After the reaction, 2 mL of special grade ethanol was added, reprecipitation was performed in 500 mL of acetonitrile, and the residue was collected by filtration. This filtrate was put into a cellulose dialysis tube (seamless cellulose tube, manufactured by Wako Pure Chemical Industries, Ltd.), both ends of the tube were tied, and then dialyzed with ion-exchanged water for 2 days. Thereafter, the contents of the tube were lyophilized to obtain 36.8 mg of a polymer (GE167-r8) into which oligoarginine was introduced.

This polymer (GE167-r8) was subjected to ¹ H-NMR measurement at 400 MHz using heavy water “DEUTRIUM OXIDE” (manufactured by Sigma-Aldrich Japan) as a heavy solvent. The obtained ¹ H-NMR spectrum is shown in FIG. In FIG. 1, the peak observed near the chemical shift of 3.8 ppm is derived from the methine group proton in the N vinylacetamide unit, and the peak observed near 3.2 ppm is derived from the methylene group proton at the δ position of arginine. To do. By combining this result with the result of the neutralization titration described above, it was found that l: m: n = 93: 5.26: 1.74 (that is, the presence of the side chain B described above with respect to the side chain A) The molar ratio is 1.74 / 5.26 = 0.33).

<Example 2>
A polymer (GE167-R8) was synthesized in the same procedure as in Example 1 except that octa-L arginine (NH ₂ -RRRRRRRR, manufactured by Hayashi Kasei Co., Ltd.) was used when the membrane-penetrating peptide was introduced.

This polymer (GE167-R8) was subjected to ¹ H-NMR measurement at 400 MHz using heavy water “DEUTRIUM OXIDE” (manufactured by Sigma-Aldrich Japan) as a heavy solvent. The obtained ¹ H-NMR spectrum is shown in FIG. In FIG. 2, the peak observed near the chemical shift of 3.8 ppm is derived from the methine group proton in the N vinylacetamide unit, and the peak observed near 3.2 ppm is derived from the methylene group proton at the δ position of arginine. To do. By combining this result with the result of the neutralization titration described above, it was found that l: m: n = 93: 5.78: 1.22 (that is, the presence of the side chain B described above with respect to the side chain A) The molar ratio is 1.22 / 5.78 = 0.21).

<Evaluation 1>
First, blood was collected from the tail of a mouse under anesthesia with ether, and the blood glucose level was measured. Subsequently, a human recombinant insulin (25 IU / mL) and a PBS solution of the polymer (0.1 w / v%) synthesized in Example 1 were injected into the nasal cavity of the mouse at an insulin dose of 10 IU / kg, high Simultaneous administration was performed so that the dose of the molecule was 0.4 mg / kg. While continuing anesthesia with ether, blood was collected from the mouse tail after 10, 30, 60, 90, and 120 minutes from the administration, and the blood glucose level was measured. The result is shown in FIG. The control in FIG. 3 corresponds to the case where a PBS solution containing neither insulin nor polymer is administered, and Comparative Example 1 corresponds to the case where a PBS solution containing only insulin in an amount equal to that in Example 1 is administered.

  As shown in FIG. 3, when the polymer of Example 1 was administered at the same time as insulin, the blood glucose level was significantly reduced as compared with the administration of Comparative Example 1 alone. Thereby, according to the polymer of the present invention, it was confirmed that the transepithelial absorption efficiency of insulin can be improved.

<Evaluation 2>
First, blood was collected from the tail of a mouse under anesthesia with ether, and the blood glucose level was measured. Subsequently, exendin-4 (50 μg / mL) and a solution of the polymer synthesized in Example 1 or Example 2 (0.1 w / v%) in PBS were placed in the nasal cavity of the mouse. Simultaneous administration was carried out so that the dose was 20 μg / kg and the polymer dose was 0.4 mg / kg. While continuing anesthesia with ether, blood was collected from the mouse tail after 10, 30, 60, 90, and 120 minutes from the administration, and the blood glucose level was measured. The result is shown in FIG. In addition, when the PBS solution which does not contain exendin-4 and a polymer | macromolecule is administered for the control | contrast in FIG. 4, the comparative example 2 is PBS solution which contains only the exendin-4 only in Example 1 and Example 2. Corresponds to the administration of

  As shown in FIG. 4, when the polymer synthesized in Example 1 or Example 2 was administered at the same time as exendin-4, the blood glucose level was lower than that of exendin-4 alone in Comparative Example 2. It had declined to the advantage. Thereby, according to the polymer of the present invention, it was confirmed that the transepithelial absorption efficiency of exendin-4 can be improved. Regarding exendin-4, it was also confirmed that the polymer synthesized in Example 1 can further improve transepithelial absorption efficiency than the polymer synthesized in Example 2.

<Evaluation 3>
[Nasal administration]
Rats (Wistar strain, bw 228-295 g) were anesthetized with urethane (1.25 g / kg, ip), and a blood cannula was placed in the femoral artery. A tracheal cannula was inserted and a small incision was made in the esophagus, and then the esophagus cannula was inserted toward the oral cavity and fixed. Furthermore, in order to avoid drug transfer from the nasal cavity to the oral cavity, the nasal palate tube was adhered, and then a solution of tulobuterol hydrochloride in PBS (30 mg / mL) and the polymer synthesized in Example 1 or Example 2 (0 0.1 w / v%) PBS solution was administered so that the dose of tulobuterol hydrochloride was 0.3 mg / body and the dose of polymer was 0.1 mg / body. Thereafter, approximately 0.5 mL of blood was collected over time via an arterial cannula. After centrifuging the blood sample, plasma was separated, and tulobuterol was quantified by LC-MS / MS. Comparative Example 3 corresponds to the case where a PBS solution containing only tulobuterol hydrochloride in the same amount as in Example 1 and Example 2 was administered.

[Intravenous administration]
Rats (Wistar strain, bw 233-270 g) were anesthetized with urethane (1.25 g / kg, ip), and a blood cannula was placed in the femoral artery. Tulobuterol hydrochloride in PBS (0.6 mg / mL) was intravenously administered so that the dose of tulobuterol hydrochloride was 0.3 mg / body, and then about 0.5 mL of blood was collected over time via an arterial cannula. went. After centrifuging the blood sample, plasma was separated, and tulobuterol was quantified by LC-MS / MS.

[BA comparative evaluation]
AUC ₀ to _∞ was calculated from the time-dependent tulobuterol concentration by moment analysis, and BA (bioavailability, bioavailability (%)) based on the following formula from each nasal AUC value with respect to intravenous AUC value Was calculated.
BA = (AUC _{nasal administration} / nasal dosage) / (AUC _{intravenous administration} / intravenous dosage) × 100

The results are shown in Table 1.

  As shown in Table 1, when the polymer synthesized in Example 1 or Example 2 was administered, the tulobuterol hydrochloride BA value was significantly higher than in the case where the polymer was not administered as in Comparative Example 1. It was. Thereby, according to the polymer of the present invention, it was confirmed that the transepithelial absorption efficiency of tulobuterol hydrochloride can be improved. In addition, regarding tulobuterol hydrochloride, it was also confirmed that the polymer synthesized in Example 2 can further improve the transepithelial absorption efficiency than the polymer synthesized in Example 1.

^{1 is} a ¹ H-NMR spectrum of a polymer according to an example of the present invention. 3 is a ¹ H-NMR spectrum of a polymer according to another example of the present invention. It is a graph which shows the change of the pharmacological effect (blood glucose level) accompanying the change of the drug nasal absorption efficiency by the polymer shown in FIG. It is a graph which shows the change of the pharmacological effect (blood glucose level) accompanying the change of the drug nasal absorption efficiency by the polymer | macromolecule shown in FIG.1 and FIG.2.

Claims (5)

  A polymer having a membrane-penetrating peptide in the side chain.   The polymer according to claim 1, wherein at least one of the amino acids constituting the membrane-penetrating peptide is a basic amino acid.   The polymer according to claim 1, which has a crosslinked structure by a covalent bond or a crosslinked structure by a non-covalent interaction.   A transepithelial absorption promoter comprising the polymer according to any one of claims 1 to 3.   A pharmaceutical preparation comprising the transepithelial absorption promoter according to claim 4 and a drug.

Images